The Manchester-based venture capital firm led the round to support product development and entry into new insurance sectors.
"This investment and our new partnership with Praetura Ventures is a powerful endorsement of our vision, our strategy and the solutions we are delivering to the insurance industry,"
Playfair Capital led the seed investment in Qureight, with backing from Meltwind, Ascension, and Cambridge Angels, to accelerate drug development partnerships.
"our next targets are pulmonary hypertension and adverse drug effects in complex lung cancer patients. This funding will allow us to use our platform to work with our biopharma partners to accelerate drug development in these areas."
The financing was co-ordinated by WG Partners to support analytical platform expansion and new therapeutics programmes.
"The investor interest we have seen is an indication of the appetite for AI-enabled precision medicines and the innovation of our unique analytical platform for mining patient data."
The oversubscribed round was co-led by Dorilton Ventures and Molten Ventures to support headcount growth.
"Our vision is to create a world in which humans can trust machines with the greatest challenges in the economy, society, and healthcare. Our customers are seeing transformative results with our no-code platform and we now have the resources to bring our platform to everyone."
The financing was led by Zetta Venture Partners alongside Amadeus Capital Partners and Speedinvest to fund international growth and product development.